摘要
Nivolumab是一种结合于程序性死亡受体-1(PD-1)的单克隆抗体,通过阻断PD-1和PD-L1及PD-L2间的相互作用,从而阻断PD-1通路介导的免疫抑制反应,包括抗肿瘤免疫反应。2014年被美国FDA批准用于黑色素瘤患者,2015年被FDA扩展批准用于非小细胞肺癌(NSCLC),是首个肺癌免疫疗法药物。本文通过对其药理作用、药动学、临床评价和安全性等进行综述。
Nivolumab is a programmed death receptor-1（ PD-1） blocking antibody. It was approved for patients of melanoma by the US Food and Drug Administration（ FDA） in 2014 and was extendedly approved as the first drug of lung cancer immunotherapy for patients of non-small cell lung cancer（ NSCLC） in 2015. Nivolumab is a monoclonal antibody combining with PD-1 receptor,which can block the immunosuppression mediated by the PD-1 pathway through blocking the interactions between PD-1 and PD-L1 and PD-L2,including anti-tumor immune response. A literature search was conducted with the key word nivolumab. The pharmacology,pharmacokinetics,clinical research,dosage,drug interactions,and safety of nivolumab were reviewed in this paper.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2016年第9期961-963,共3页
Chinese Journal of New Drugs
